MX2018009405A - Sintesis y composicion de bibliotecas de rapafucina. - Google Patents

Sintesis y composicion de bibliotecas de rapafucina.

Info

Publication number
MX2018009405A
MX2018009405A MX2018009405A MX2018009405A MX2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A
Authority
MX
Mexico
Prior art keywords
synthesis
rapafucin
libraries
composition
compounds
Prior art date
Application number
MX2018009405A
Other languages
English (en)
Spanish (es)
Inventor
Liu Jun
Wang Jingxin
Guo Zufeng
hong Sam
Liu Wukun
Peng Hanjing
Das Manisha
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2018009405A publication Critical patent/MX2018009405A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2018009405A 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina. MX2018009405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291437P 2016-02-04 2016-02-04
PCT/US2017/016481 WO2017136708A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Publications (1)

Publication Number Publication Date
MX2018009405A true MX2018009405A (es) 2018-11-09

Family

ID=59501078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009405A MX2018009405A (es) 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina.

Country Status (8)

Country Link
US (1) US10662220B2 (enExample)
EP (1) EP3411413A4 (enExample)
JP (2) JP6891183B2 (enExample)
CN (1) CN108713028B (enExample)
AU (1) AU2017214550B2 (enExample)
CA (1) CA3013589A1 (enExample)
MX (1) MX2018009405A (enExample)
WO (1) WO2017136708A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852183B (zh) 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法
US10815489B2 (en) 2015-03-13 2020-10-27 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-tRNA synthetase and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CN108697729B (zh) 2016-02-04 2023-05-09 约翰霍普金斯大学 新型GLUT抑制剂rapaglutin及其用途
WO2017136708A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Synthesis and composition of rapafucin libraries
AU2017214557B2 (en) * 2016-02-04 2022-05-19 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
EP3636807A4 (en) * 2017-06-09 2021-07-28 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND WITH HIGH MEMBRANE PERMEABILITY AND LIBRARY WITH IT
US12594275B2 (en) 2019-02-07 2026-04-07 The Regents Of The University Of California Immunophilin binding agents and uses thereof
KR102994657B1 (ko) * 2019-03-15 2026-07-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
WO2021067405A1 (en) * 2019-10-01 2021-04-08 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
TW202126323A (zh) * 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛(Rapafucin)衍生化合物及其使用方法
WO2021071931A1 (en) 2019-10-07 2021-04-15 The Johns Hopkins University Three-dimentional surface for protein and small molecule microarrays
CN120271673A (zh) * 2024-01-08 2025-07-08 重庆医科大学 一种化合物、包含其的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
CN1187127A (zh) * 1995-06-07 1998-07-08 吉尔福特药品有限公司 旋转异构酶活性抑制剂
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
JP2002503667A (ja) * 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2010004304A1 (en) * 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
AU2011336727B2 (en) * 2010-11-30 2016-11-03 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
US10167259B2 (en) * 2013-06-14 2019-01-01 The Board Of Regents Of The University Of Texas System Allosteric inhibitors of proteasome and methods of use thereof
WO2017136708A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Synthesis and composition of rapafucin libraries

Also Published As

Publication number Publication date
EP3411413A1 (en) 2018-12-12
JP2019510738A (ja) 2019-04-18
JP7158532B2 (ja) 2022-10-21
JP6891183B2 (ja) 2021-06-18
CN108713028A (zh) 2018-10-26
US20190092808A1 (en) 2019-03-28
WO2017136708A1 (en) 2017-08-10
JP2021138726A (ja) 2021-09-16
EP3411413A4 (en) 2019-09-18
US10662220B2 (en) 2020-05-26
AU2017214550B2 (en) 2024-03-07
CN108713028B (zh) 2021-12-28
CA3013589A1 (en) 2017-08-10
AU2017214550A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
IL286833A (en) Compositions containing brazzein
IL282682A (en) Improved synthesis of key intermediate of kras g12c inhibitor compound
DK4021901T3 (da) Substituerede pyridopyrimidinonylforbindelser som er nyttige som t-celleaktivatorer
PL3844147T3 (pl) Związki chemiczne
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
EP4129997A4 (en) Octahydropyrazinodiazanaphthyridine dione compounds
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CO2019003709A2 (es) Conjugados de pirrolobenzodiazepina
LT3814347T (lt) Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
EA201992235A1 (ru) Синтез ингибитора mcl-1
PT4058453T (pt) Síntese melhorada de composto inibidor de kras g12c
CL2018003132A1 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
EP3842412A4 (en) BIODEGRADABLE COMPOUND, LIPID PARTICLES, COMPOSITION WITH LIPID PARTICLES AND KIT
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
IL310528A (en) Pyrazolopyridinone compounds
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
DK3648743T3 (da) Pressede tabletter, der omfatter nitrooxyforbindelser
DK3866931T3 (da) Forbindelser indeholdende deuterium
DK3681885T3 (da) Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
PL3405178T3 (pl) Preparaty/kompozycje zawierające inhibitor btk
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser